ALLO
HealthcareAllogene Therapeutics, Inc. · Biotechnology · $490M
What is Allogene Therapeutics, Inc.?
Allogene Therapeutics is a clinical-stage immuno-oncology company focused on off-the-shelf allogeneic CAR T cell therapies for cancer. Founded in 2018 and headquartered in South San Francisco, it is building a pipeline targeting blood cancers and solid tumors.
Allogene engineers donor-derived T cells — rather than a patient's own — to attack cancer cells, aiming to make CAR T therapy faster and more scalable. The company generates no commercial revenue yet; it funds operations through partnerships and capital raises while advancing multiple candidates through Phase I and Phase I/II clinical trials. Collaboration agreements with Pfizer, Servier, Cellectis, and Notch Therapeutics support its research and development efforts.
Allogene was founded in 2018 and is headquartered in South San Francisco, California.
- UCART19 — allogeneic CAR T for CD19-positive B-cell ALL
- ALLO-501 / ALLO-501A — anti-CD19 CAR T for non-Hodgkin and large B-cell lymphoma
- ALLO-715 / ALLO-605 — allogeneic CAR T candidates targeting multiple myeloma
- ALLO-819 — CAR T candidate for acute myeloid leukemia
- DLL3 program — targeting small cell lung cancer and neuroendocrine tumors
Is ALLO a Good Stock to Buy?
UQS Score rates ALLO as Poor overall, reflecting the early-stage nature of its pipeline and the significant uncertainties that come with pre-revenue biotech.
The one area where ALLO stands out relative to its profile is Risk — the company carries a Strong Risk pillar label, which in this context reflects a balance sheet that provides a degree of runway for ongoing trials rather than near-term solvency pressure.
Quality, Moat, and Growth all register as Weak, consistent with a company that has no approved products, no commercial revenue, and a competitive landscape where clinical outcomes remain unproven. Valuation is rated Elevated, suggesting the market is already pricing in optimistic scenarios.
See the full five-pillar breakdown and detailed financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ALLO pay dividends?
No — Allogene Therapeutics, Inc. does not currently pay a dividend.
Allogene does not pay a dividend, which is typical for clinical-stage biotechs. All available capital is directed toward research, clinical trials, and pipeline development. Income-focused investors should look elsewhere; those interested in ALLO are generally seeking exposure to potential long-term pipeline value rather than current income.
When does ALLO report earnings?
Allogene Therapeutics reports financial results on a quarterly cadence, standard for US-listed companies.
As a pre-revenue company, quarterly reports focus on cash position, operating expenses, and clinical trial progress rather than sales or profit metrics. Key updates tend to center on pipeline milestones and partnership developments.
For the most recent quarter's results and upcoming reporting dates, visit Allogene Therapeutics' investor relations page directly.
ALLO Price History
-91.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Allogene Therapeutics, Inc.?
Based on Allogene Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
ALLO Long-term Outlook
With a Weak Growth pillar and no approved products, Allogene's near-term trajectory depends almost entirely on clinical trial readouts and the ability to advance candidates into later-stage studies. The Strong Risk pillar suggests the company has managed its balance sheet carefully, but an Elevated Valuation label means the current price may already reflect hopeful outcomes. Progress in the allogeneic CAR T field — and differentiation from autologous therapies — will be central to any long-term value creation.
Growth drivers
- Positive clinical data from ALLO-501A or ALLO-715 advancing to later-stage trials
- Expansion of collaboration agreements with established pharma partners
- Broader adoption of allogeneic CAR T as a scalable alternative to autologous therapies
Key risks
- Clinical trial failures or safety signals that stall pipeline progression
- Elevated valuation leaving little margin of safety if milestones are missed
- Competitive pressure from autologous CAR T leaders and other allogeneic programs
ALLO vs Peers
Allogene operates in a small-cap clinical-stage space alongside other pre-revenue biotechs navigating similar development and funding challenges.
CorMedix focuses on anti-infective solutions for catheter-related bloodstream infections, a narrower and more near-term commercial focus than Allogene's broad oncology pipeline.
Crescent Biopharma is an early-stage oncology company pursuing differentiated cancer therapies, competing with Allogene for investor attention in the speculative biotech space.
Palatin targets melanocortin receptor pathways for conditions including sexual dysfunction and inflammation, representing a very different therapeutic area from Allogene's immuno-oncology focus.
Frequently Asked Questions
What does Allogene Therapeutics do?
Allogene Therapeutics develops allogeneic CAR T cell therapies — treatments made from donor T cells rather than a patient's own — designed to fight various blood cancers and solid tumors. Its pipeline includes candidates targeting B-cell malignancies, multiple myeloma, acute myeloid leukemia, and small cell lung cancer, all currently in clinical trials.
Does ALLO pay dividends?
No, Allogene does not pay a dividend. As a clinical-stage company with no commercial revenue, it reinvests all available capital into research and clinical development. Dividend income is not a feature of this investment.
When does ALLO report earnings?
Allogene reports on a quarterly cadence typical of US-listed companies. Because it is pre-revenue, reports focus on cash runway and pipeline updates rather than sales figures. Check the company's investor relations page for the current reporting schedule.
Is ALLO a good stock to buy?
UQS Score rates ALLO as Poor overall, driven by Weak Quality, Moat, and Growth pillars alongside an Elevated Valuation. The Strong Risk pillar reflects relative balance sheet stability, but the overall profile signals high uncertainty. Investors should weigh pipeline risk carefully before considering a position.
Is ALLO overvalued?
The UQS Valuation pillar for ALLO is rated Elevated, suggesting the current market price may already incorporate optimistic clinical outcomes. For a pre-revenue biotech, valuation is inherently speculative and tied to trial results. The full valuation breakdown is available to UQS Pro members.
How does ALLO compare to its competitors?
Allogene sits alongside other small-cap clinical-stage biotechs such as CorMedix, Crescent Biopharma, and Palatin Technologies. Each pursues different therapeutic areas and development timelines. Allogene's distinguishing bet is on allogeneic — off-the-shelf — CAR T technology, which differs meaningfully from both its listed peers and larger autologous CAR T players.
What is ALLO's market cap bracket?
Allogene Therapeutics is classified as a small-cap company. This places it in a segment of the market characterized by higher volatility, greater sensitivity to clinical news, and more limited access to capital compared to large- or mega-cap peers.
Who founded Allogene Therapeutics?
Allogene Therapeutics was founded in 2018. Founding and leadership details are widely available through the company's public filings and its investor relations website for those seeking background on the executive team.
Is ALLO a long-term quality investment?
As a long-term quality indicator, ALLO's UQS profile — with Weak scores across Quality, Moat, and Growth — reflects the structural challenges of a pre-revenue clinical-stage biotech. Long-term value depends on clinical success that has not yet been demonstrated. UQS Pro members can access the complete pillar analysis.
What is the main competitive advantage of Allogene Therapeutics?
Allogene's core thesis is that allogeneic CAR T — using pre-manufactured donor cells — can be delivered faster and at lower cost than autologous therapies that require a patient's own cells. If validated clinically, this off-the-shelf approach could differentiate it from established CAR T competitors. The Moat pillar currently rates this advantage as Weak, reflecting unproven commercial execution.
What sector does ALLO belong to?
Allogene Therapeutics operates in the Healthcare sector, specifically within clinical-stage immuno-oncology. Investors can explore other [Healthcare sector stocks](/sector/healthcare) rated by UQS Score for broader context.
Is ALLO a growth stock or value stock?
Based on its UQS profile, ALLO fits neither category cleanly. The Growth pillar is Weak — reflecting no revenue and uncertain pipeline timelines — while the Valuation pillar is Elevated, ruling out a traditional value framing. It is best characterized as a speculative clinical-stage biotech.
Unlock the Full ALLO Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare ALLO against sector peers side by side
- ✓Track pipeline and risk signals in one dashboard
- ✓Get the full analyst-grade view for Pro members
Pro Analysis
ALLO — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Apr 22, 2026 | 20.5 | 0.0 | 18.0 | 18.5 | 82.4 | 0.0 | -1.0 |
| Apr 2, 2026 | 21.5 | 0.0 | 18.0 | 23.1 | 82.4 | 0.0 | — |
ALLO — Pillar Breakdown
Quality
— 0.0/100 (25%)Allogene Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 18.5/100 (20%)Allogene Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 82.4/100 (15%)Allogene Therapeutics, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Allogene Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 18/100 (25%)Allogene Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ALLO.
Score Composition
Financial Data
More Stock Analysis
How is the ALLO UQS Score Calculated?
The UQS (Unified Quality Score) for Allogene Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Allogene Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Allogene Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.